Rezolute, Inc. (RZLT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.58+0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RZLT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Achieve regulatory alignment and approval for ersodetug as a treatment for congenital hyperinsulinism based on Phase 3 sunRIZE study data and FDA engagement.
Stated as a priority in 3 of last 3 quarters. Management has presented expanded Phase 3 sunRIZE data showing clinically relevant glycemic improvements and engaged FDA in a Type B meeting, with FDA encouraging submission of comprehensive datasets. The trajectory shows persistent focus and ongoing regulatory engagement, with no approval yet but clear progress toward alignment.
“FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation.”
“Company is assessing longer-term efficacy and safety in open-label extension phase.”
“Management confident in potential to achieve FDA alignment on path to approval.”
Enroll all participants in the Phase 3 upLIFT study for tumor hyperinsulinism and announce topline results in second half of 2026.
Newly stated in 2026-Q2 and 2026-Q3 disclosures. The upLIFT study is halfway enrolled with 8 participants, 6 meeting the primary endpoint of at least 50% reduction in IV glucose requirements. Topline results are expected in the second half of 2026. The trajectory is delivering interim positive data and progressing enrollment as planned.
Control research and development and general administrative expenses to manage net loss and cash burn.
Stated as a priority in 4 of last 4 quarters. R&D expenses decreased from $15.3M in 2025-Q3 to $11.4M in 2026-Q3, and net loss improved from $18.9M to $16.2M year-over-year. Operating expenses and net loss show a modest improving trend, indicating management is delivering some cost control and cash burn management.
“R&D expenses were $11.4 million, down from $15.3 million year ago.”
“Net loss was $16.2 million compared with $18.9 million for same period last year.”
“Operating expenses totaled $17.4 million, down from $20.0 million year ago.”
“Net loss was $24.4 million for the quarter.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.91x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, the US dollar, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.